Retatrutide appears to be a new pharmaceutical in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By boosting these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately contributes to significant weight loss. While